Abstract library

40 results for "Otaño".
#2230 Does Somatostatin Receptor (SSR) Positive Tumor Volume Determined on Ga68 DOTANOC PET/CT in Patients with Paraganglioma (PGL)/Pheochromocytoma(PCC) Correlate with Biomarkers? An Explorative Study
Introduction: SSR PET/CT is used in workup of pts with PCC/ PGL. Correlation of tumour burden on PET & biomarkers 24 hr Urine Metanephrines (UMET), normetanephrine (UNMET), UMET:creatinine ratio (MET:Crea),UNMET:creatinine (UNMET:crea) & Chromogranin A (CGA) has not been done.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Rachelle Steyn
Authors: Steyn R, Prasad V
#651 Additional Value of New Molecular Imaging Tracers in the Detection of Recurrent/Residual Disease in Patients with Neuroendocrine Tumors
Introduction: Recent studies have proposed new molecular imaging tracers, such as 18F-DOPA and 68Ga-DOTANOC, for the detection of recurrent/residual neuroendocrine tumors (NET) in case of negative conventional imaging modalities.
Conference: 10th Annual ENETS Conference (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Andrea Lania
#517 Initial Experience of Biological Stability and Image Timing of Ga-68 DOTANOC in Somatostatin Receptor (sstr) Expressing Organ and Tumor
Introduction: Since Ga68 DOTATATE has a high affinity to only sstr2 but no affinity to sstr3 and sstr5, Ga68 DOTANOC has been suggested to be a better radioligand with higher affinity to sstr3 and sstr5 and high affinity to sstr2, as well.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Emre Demirci
Authors: Demirci E, Kabasakal L, Ocak M, Aygun A, ...
Keywords: Octreotide PET
#1820 A Nuclear Combination in Heterogeneous Metastatic Neuroendocrine Tumors
Introduction: Therapy with 177Lu-DOTATATE provides an objective response in neuroendocrine tumors (NET).
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: MD Vanessa Sousa
Keywords: PRRT, 68Ga-DOTANOC
#26 Molecular imaging of gastroenteropancreatic neuroendocrine tumours with Ga-68 DOTANOC PET/CT and correlation with an immunhistochemical quantification of somatostatin receptors using novel monoclonal and polyclonal antibodies
Introduction: Receptor PET/CT with somatostatin analogues marked with Gallium-68 (SMS-R-PET/CT) is currently the golden standard in diagnosing gastroenteropancreatic neuroendocrine tumors (GEP-NET), which are known for an overexpression of somatostatin receptors (SSTRs).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Daniel Kaemmerer
#987 Evaluation of the Added Value of Diffusion-Weighted Imaging to Conventional MRI in Pancreatic Neuroendocrine Tumors and Comparison with 68Ga-DOTANOC PET/CT
Introduction: Pancreatic neuroendocrine tumors (pNETs) are often difficult to detect because of small size and have variable prognosis related to grading and staging.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr. Maria Gabriella Brizi
#2185 Nonfunctional Pancreatic Neuroendocrine Tumor (NF PNET) Imaging and Evaluation Using 18F-FDG and 68Ga- DOTANOC-PET/CT: Initial Data of a Prospective Study
Introduction: Predicting aggressive behavior of NF PNET still remains controversial. It is known that lymph node metastases are rare but possible also on small (1-2 cm) NF-PNET. Positive 18F-FDG-PET/CT avidity is associated with poor prognosis in NETs.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Susanna Majala
#422 The Somatostatin Analogue Octreotide Inhibits Growth of Neuroendocrine Tumor Cells by Triggering Janus Faced Proteins
Introduction: Octreotide is a somatostatin analogue, which improves the management of neuroendocrine tumor (NET) patients. Octreotide acts through somatostatin receptors (SSTRs). However, the molecular mechanisms leading to successful therapy or curative effects are largely unknown, particularly when SSTRs levels are low or absent.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Su-Chen Li
Authors: Li S C, Martijn C, Cui T, Essaghir A, ...
#524 Sunitinib in a MEN-1 Patient with Small Cell Neuroendocrine Tumor of the Thymus
Introduction: MEN-1 is an autosomal dominant disease caused by mutation of the oncosuppressor gene menin. MEN-1 is typically associated with hyperparathyroidism, islet cell tumors and pituitary adenomas, but it can also be associated with other neoplasms, such as thymic carcinoids.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Prof Giovannella Palmieri
#557 The Role of Chemotherapy in the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): The Large Experience of the Spanish National Tumor Registry (RGETNE)
Introduction: GEPNETs represent a heterogenous family of tumors of challenging clinical management. Treatment of advanced disease is evolving, including some recent relevant achievements with novel targeted agents. How to best integrate these new agents with conventional chemotherapy(CT) is still a matter of debate.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD Rocio Garcia-Carbonero
Keywords: chemotherapy
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.